Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

the Japanese Ixekizumab Study Group

Research output: Contribution to journalArticlepeer-review

91 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)'. Together they form a unique fingerprint.

Medicine & Life Sciences